What is First Light Diagnostics?
First Light Diagnostics is at the forefront of developing and commercializing advanced diagnostic products designed for the rapid and sensitive detection of life-threatening infections. Leveraging proprietary single-cell and single-molecule detection technology, the company aims to provide solutions that combine the accuracy of sophisticated laboratory tests with enhanced speed, cost-effectiveness, and user-friendliness. This technological advantage is poised to significantly improve patient outcomes, reduce overall healthcare expenditures, and combat the spread of antibiotic resistance by enabling early and precise antibiotic selection.
How much funding has First Light Diagnostics raised?
First Light Diagnostics has raised a total of $7.1M across 4 funding rounds:
Private Equity
$811K
Unspecified
$4.3M
Debt
$1M
Debt
$1M
Private Equity (2016): $811K, investors not publicly disclosed
Unspecified (2019): $4.3M led by BARDA
Debt (2020): $1M supported by PPP
Debt (2021): $1M featuring PPP
Key Investors in First Light Diagnostics
PPP
Public-Private Partnership
BARDA
Undisclosed investor participating in the funding round.
What's next for First Light Diagnostics?
With a recent major strategic investment, First Light Diagnostics is well-positioned to accelerate its commercialization efforts and expand the reach of its breakthrough diagnostic technologies. The company's focus on addressing critical healthcare challenges, such as early infection detection and antibiotic resistance, aligns with growing market demands and governmental initiatives. Future growth will likely involve scaling manufacturing, expanding its product portfolio, and forging strategic partnerships to ensure its innovative solutions are widely adopted within clinical settings, thereby solidifying its market leadership in rapid diagnostics.
See full First Light Diagnostics company page
